Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Sales | 60,755 | 59,292 | 59,406 | 67,212 | 55,770 |
| Cost of Goods | 45,119 | 43,019 | 38,936 | 49,153 | 44,281 |
| Gross Profit | 15,636 | 16,273 | 20,470 | 18,059 | 11,489 |
| Operating Expenses | 9,738 | 18,503 | 12,003 | 15,958 | 12,867 |
| Operating Income | 6,017 | -2,211 | 9,403 | 2,254 | -1,097 |
| Interest Expense | 138 | 137 | 137 | 99 | 109 |
| Other Income | 155 | 377 | 507 | 980 | -445 |
| Pre-tax Income | 6,034 | -1,971 | 9,773 | 3,135 | -1,651 |
| Income Tax | 2,332 | 504 | 3,268 | 1,703 | 492 |
| Net Income Continuous | 3,702 | -2,475 | 6,505 | 1,432 | -2,143 |
| Net Income | $3,702 | $-2,475 | $6,505 | $1,432 | $-2,143 |
| EPS Basic Total Ops | 0.12 | -0.08 | 0.21 | 0.05 | -0.07 |
| EPS Basic Continuous Ops | 0.12 | -0.08 | 0.21 | 0.05 | -0.07 |
| EPS Diluted Total Ops | 0.12 | -0.08 | 0.21 | 0.05 | -0.07 |
| EPS Diluted Continuous Ops | 0.12 | -0.08 | 0.21 | 0.05 | -0.07 |
| EBITDA(a) | $9,835 | $1,805 | $13,520 | $6,528 | $3,061 |